Brief: Antengene Says Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio For Relapsed Or Refractory DLBCL
17/12/2025 01:23
Dec 17 (Reuters) - Antengene Corp Ltd 6996.HK: MALAYSIAN NATIONAL PHARMACEUTICAL REGULATORY AGENCY APPROVES XPOVIO FOR RELAPSED OR REFRACTORY DLBCL Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106